Compare ENTX & BTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENTX | BTA |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 127.4M |
| IPO Year | 2018 | N/A |
| Metric | ENTX | BTA |
|---|---|---|
| Price | $2.37 | $9.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 107.9K | 21.9K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.22% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 25.25 | N/A |
| 52 Week Low | $1.50 | $8.59 |
| 52 Week High | $3.22 | $10.62 |
| Indicator | ENTX | BTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 40.48 |
| Support Level | $2.26 | $9.37 |
| Resistance Level | $2.53 | $9.44 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 6.05 | 14.29 |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Blackrock Long-term Municipal AdtgTrust is a diversified closed-end investment trust. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The fund, under normal market conditions, invests a majority of its managed assets in municipal obligations and derivative instruments with exposure to such municipal obligations, in each case that are expected to pay interest or income that is exempt from U.S. federal income tax. Its investment portfolio comprises dollar-weighted, long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund's investments have exposure to various sectors such as Corporate, Health, County/City/Special District/School District, Transportation, Education, Utilities, State, Tobacco, etc.